Recursion Pharmaceuticals, Inc. RXRX Loss Contingency Accrual
Loss Contingency Accrual at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LossContingencyAccrualAtCarryingValue.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company’s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company’s exposure and enable it to recover a portion of any amount it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of June 30, 2026 and December 31, 2025, as no amounts were probable.
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s loss contingency accrual?
- Recursion Pharmaceuticals, Inc. (RXRX) reported loss contingency accrual of $0 in Q2 2026.
- What does loss contingency accrual mean?
- Loss Contingency Accrual
Ask your AI about Recursion Pharmaceuticals, Inc.'s loss contingency accrual.
Connect your AI assistant and compare it to peers, right in your chat.
